GNPX News and Press, Genprex Inc. From 02/01/21

Genprex shares rise ([[GNPX]] +6.5%) after the clinical-stage gene therapy company lists out its 2020 achievements and expected milestones for the year in a letter to its shareholders.The progress on the company's Acclaim-1 and Acclaim-2 trials evaluating REQORSA separately in combinatio...

Major milestones achieved in advancing gene therapies for lung cancer and diabetes Company looks toward launching key clinical trials in lung cancer in 2021 Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-sta...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...

Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th Live Investor Conference & Webinar: Small and Microcap Company Showcase on February 4th Company executives will share vision and answer audience questions at VirtualInvestorConfer...

Company to provide update on upcoming clinical trials for the treatment of non-small cell lung cancer and an overview of its diabetes gene therapy Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy co...

Can These 4 Penny Stocks Reach New Highs in 2021? This year has already gotten off to a great start for penny stocks . We see a few industries that continue to command interest. With so much occurring in the world right now, it’s best to start by picking a trading strategy be...

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020. These companies on average are unprofitable and tra...

Presentation to Highlight Company’s Recent Advancements on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy compan...

Presentation to Highlight the Company’s Recent Progress on its Upcoming Clinical Trials for the Treatment of Non-Small Cell Lung Cancer Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy compan...

Genprex ([[GNPX]] +0.4%) has passed the final release tests of scaled-up clinical grade production to supply REQORSA immunogene therapy for upcoming Acclaim-1 and Acclaim-2 trials in non-small cell lung cancer.The company recently announced the completion of the techn...